Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-414 plus chemoradiation and adjuvant temozolomide versus placebo in newly diagnosed EGFR-amplified glioblastoma
MOH_2017-12-21_000098Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2015
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing ABT-414 arm with Placebo arm (2 arms). Primary endpoints: progression-free survival and overall survival. Started Sep 2015; status: active, not recruiting.
02
Drugs
depatuxizumab mafodotin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on MOH_2017-12-21_000098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-21_000098.